While the poor outcome of BCL2-positive HNSCC patients and the ability of venetoclax to inhibit cell proliferation, invasion/migration, and resistance to apoptosis have been demonstrated, a novel and unique finding of our study is the enhanced cisplatin-mediated cytotoxicity in combination with venetoclax [6,7,25,26]. Here, BCL2 is linked to head and neck squamous cell carcinoma.